Table 3.

Proportion of uveitic eyes with active disease and macular edema over 54 and 48 months, respectively, by implant vs. systemic therapy treatment group in the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study.

		Estimated Proportion with Condition (95% CI)		Ratio of Odds Compared to Baseline Odds of Having Condition (95% CI)		Estimated Treatment Effect (95% CI) †
	Sample size*	Implant	Systemic	Implant	Systemic	Implant: Systemic	P value
Uveitis Activity, % active
Enrollment	471	79% (71%, 85%)	76% (69%, 83%)	n/a	n/a	n/a
12 months	434	16% (10%, 22%)	37% (26%, 47%)	0.05 (0.02, 0.09)	0.19 (0.11, 0.30)	0.27 (0.12, 0.55)	<0.001
24 months	429	13% (7%, 18%)	31% (22%, 41%)	0.04 (0.02, 0.07)	0.14 (0.07, 0.23)	0.28 (0.13, 0.59)	<0.001
36 months	404	9% (4%, 14%)	23% (14%, 32%)	0.03 (0.01, 0.05)	0.09 (0.04, 0.16)	0.30 (0.11, 0.69)	0.006
48 months	390	9% (4%, 14%)	27% (18%, 35%)	0.03 (0.01, 0.05)	0.11 (0.06, 0.19)	0.23 (0.09, 0.48)	<0.001
54 months	371	10% (4%, 16%)	21% (13%, 29%)	0.03 (0.01, 0.06)	0.08 (0.04, 0.14)	0.35 (0.14, 0.82)	0.016
Macular edema, %
Enrollment	436	41% (32%, 51%)	40% (31%, 50%)	n/a	n/a	n/a
12 months	385	21% (14%, 29%)	30% (21%, 39%)	0.39 (0.25, 0.57)	0.64 (0.43, 0.93)	0.60 (0.34, 1.05)	0.064
24 months	403	22% (14%, 30%)	31% (22%, 40%)	0.41 (0.25, 0.60)	0.67 (0.46, 0.96)	0.60 (0.33, 1.03)	0.069
36 months	359	22% (14%, 30%)	23% (15%, 33%)	0.39 (0.25, 0.58)	0.46 (0.28, 0.71)	0.86 (0.46, 1.49)	0.615
48 months	356	19% (12%, 27%)	22% (15%, 31%)	0.33 (0.19, 0.52)	0.43 (0.28, 0.63)	0.78 (0.39, 1.38)	0.406

CI = 95% confidence interval; SE = standard error.

^*Sample size: the number of eyes with uveitis with data available at each visit.

^†At each of the follow-up time points, the “estimated treatment effect” is the ratio of odds ratios with 95% CIs. A ratio of odds ratios less than 1 favors implant.